Itraconazole

Generic Name: Itraconazole

Brand Names: Sporanox, Tolsura

Drug Type: Small Molecule

Chemical Formula: C_₃₅H_₃₈Cl_₂N_₈O_₄

CAS Number: 84625-61-6

Unique Ingredient Identifier: 304NUG5GF4

Background: One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.

Indication: For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.

Associated Conditions: Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases

Associated Therapies: -

Clinical Trials

A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CC-92480
Drug: Itraconazole
Drug: Digoxin
Drug: Rifampin
Drug: Rosuvastatin

First Posted Date: 2022-05-25

Last Posted Date: 2023-04-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT05389722

Locations: 🇺🇸
Covance Clinical Research Unit - Dallas, Dallas, Texas, United States

A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor

Phase 1

Active, not recruiting

Conditions: Solid Tumors

Interventions: Drug: BI 907828
Drug: Rifampicin
Drug: Itraconazole

First Posted Date: 2022-05-12

Last Posted Date: 2024-11-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 34

Registration Number: NCT05372367

Locations: 🇪🇸
Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain
🇧🇪
Brussels - UNIV Saint-Luc, Bruxelles, Belgium
🇪🇸
Hospital Quiron. I.C.U., Barcelona, Spain

and more 4 locations

Drug-drug Interaction Study of SPH3127

Phase 1

Completed

Conditions: Drug Drug Interaction

Interventions: Drug: SPH3127 tablet
Drug: Itraconazole
Drug: Rifampin

First Posted Date: 2022-05-03

Last Posted Date: 2022-07-29

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 40

Registration Number: NCT05359055

Locations: 🇨🇳
West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China

A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Selpercatinib
Drug: Itraconazole
Drug: Rifampin

First Posted Date: 2022-04-21

Last Posted Date: 2022-04-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT05338489

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: MYK-224
Drug: Itraconazole
Drug: Verapamil

First Posted Date: 2022-03-31

Last Posted Date: 2023-01-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 45

Registration Number: NCT05304533

Locations: 🇺🇸
Local Institution - 0001, Dallas, Texas, United States

Drug-drug Interaction Study With GLPG3667 and Itraconazole in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG3667
Drug: Itraconazole

First Posted Date: 2022-03-09

Last Posted Date: 2022-05-25

Lead Sponsor: Galapagos NV

Target Recruit Count: 14

Registration Number: NCT05272683

Locations: 🇨🇦
Altasciences, Montréal, Canada

PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.

Phase 1

Completed

Conditions: Healthy Adults

Interventions: Drug: Sitravatinib 50 mg
Drug: Sitravatinib 100 mg
Drug: Itraconazole
Drug: Rifampin

First Posted Date: 2022-02-24

Last Posted Date: 2024-05-08

Lead Sponsor: Mirati Therapeutics Inc.

Target Recruit Count: 36

Registration Number: NCT05255276

Locations: 🇺🇸
Labcorp Drug Development Clinical Research Unit, Dallas, Texas, United States

A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With Itraconazole

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: AZD4831
Drug: Itraconazole

First Posted Date: 2022-02-11

Last Posted Date: 2022-08-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 21

Registration Number: NCT05236543

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: LY3410738
Drug: Itraconazole
Drug: Carbamazepine

First Posted Date: 2022-01-25

Last Posted Date: 2022-12-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 27

Registration Number: NCT05205447

Locations: 🇺🇸
LabCorp CRU, Inc., Daytona Beach, Florida, United States

Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tepotinib (HydroChloride hydrate)
Drug: Itraconazole

First Posted Date: 2022-01-24

Last Posted Date: 2024-02-20

Lead Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Target Recruit Count: 18

Registration Number: NCT05203822

Locations: 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy